Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 16/20 | 1.00 |
| ▸ | HTR1B | P28222 | 14/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13533349 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1ADRD2 | |
| SCHEMBL8124390 | 0.91 | HTR1D (0.83) | HTR1DHTR1BHTR1ADRD2 | |
| SCHEMBL13534482 | 0.84 | HTR1D (0.77) | HTR1DHTR1BHTR1ADRD2 | |
| SCHEMBL8314559 | 0.84 | HTR1D (1.00) | HTR1DHTR1BHTR1ADRD2 | |
| SCHEMBL8312369 | 0.81 | HTR1D (1.00) | HTR1DHTR1BHTR1A | |
| SCHEMBL8317482 | 0.81 | HTR1D (0.74) | HTR1DHTR1BHTR1ADRD2 | |
| SCHEMBL8887262 | 0.79 | HTR1D (1.00) | HTR1DHTR1BHTR1ADRD2 | |
| SCHEMBL7206145 | 0.78 | HTR1A (0.65) | HTR1DHTR1BHTR1ADRD2 | |
| SCHEMBL8784460 | 0.77 | HTR1A (0.67) | HTR1DHTR1BHTR1ADRD2 | |
| U-92,016-A SCHEMBL29462318 | 0.76 | HTR1A (1.00) | HTR1DHTR1BHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-0510068-B1 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | UPJOHN CO (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5650427-A | ANTIDEPRESSANTS | THE UPJOHN COMPANY (US) | 1997-07-22 | — | — | US | disclosed |
| US-5461061-A | Antidepressants | WIKSTROM HAKAN V (NL) | 1995-10-24 | — | — | US | disclosed |
| US-5288748-A | Antidepressants | THE UPJOHN COMPANY (US) | 1994-02-22 | — | — | US | disclosed |
| EP-0510068-A1 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | PHARMACIA & UPJOHN COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| WO-1991011435-A2 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | THE UPJOHN COMPANY (US) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1D 36/4885HTR1B 21/4885HTR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.